New 20-Year Data Published in Urologic Oncology Validates Adverse Pathology as Predictor of Prostate Cancer Outcomes in Clinically Low-Risk Patients
/PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the publication of results underscoring the...
Source: prnewswire.com